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Introduction: Patients with severe acute exacerbations of asthma often receive inappropriate antibiotic treatment.
We aimed to determine whether serum procalcitonin (PCT) levels can effectively and safely reduce antibiotic
exposure in patients experiencing exacerbations of asthma.
Methods: In this randomized controlled trial, a total of 216 patients requiring hospitalization for severe acute
exacerbations of asthma were screened for eligibility to participate and 169 completed the 12-month follow-up
visit. Patients were randomized to either PCT-guided (PCT group) or standard (control group) antimicrobial therapy.
In the control group, patients received antibiotics according to the attending physician’s discretion; in the PCT
group, patients received antibiotics according to an algorithm based on serum PCT levels. The primary end point
was antibiotic exposure; secondary end points were clinical recovery, length of hospital stay, clinical and laboratory
parameters, spirometry, number of asthma exacerbations, emergency room visits, hospitalizations and need for
corticosteroid use due to asthma.
Results: PCT guidance reduced antibiotic prescription (48.9% versus 87.8%, respectively; P < 0.001) and antibiotic
exposure (relative risk, 0.56; 95% confidence interval, 0.44 to 0.70; P < 0.001) compared to standard therapy. There
were no significant differences in clinical recovery, length of hospital stay or clinical, laboratory and spirometry
outcomes in both groups. Number of asthma exacerbations, emergency room visits, hospitalizations and need for
corticosteroid use due to asthma were similar during the 12-month follow-up period.
Conclusion: A PCT-guided strategy allows antibiotic exposure to be reduced in patients with severe acute
exacerbation of asthma without apparent harm.
Trial registration: Chinese Clinical Trial Register ChiCTR-TRC-12002534 (registered 26 September 2012)Introduction
Asthma is a problem worldwide, with an estimated
incidence of 300 million affected individuals and 250,000
annual deaths from asthma [1]. Acute exacerbations of
asthma account for nearly 2 million emergency department
(ED) visits and 500,000 admissions each year in the United* Correspondence: longwei2290@163.com; huanggaozhong@medmail.com.cn
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unless otherwise stated.States, frequently ranking as a major cause of absence from
work and decreased productivity and incurring the greatest
health-care costs [2,3]. Severe exacerbations of asthma are
potentially life-threatening and often put patients at in-
creased risk of ED admission and hospitalization.
Because most exacerbations of asthma are associated
with viral respiratory tract infection (RTI) and bacterial
infection seems to play only a minor role, global asthma
management guidelines do not recommend routine use
of antibiotics [4]. However, in countries with high pre-
scription rates for antibiotics, many asthma patients withtd. This is an Open Access article distributed under the terms of the Creative
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biotic overuse and bacterial resistance [5-7]. In the United
States, approximately 22% of acute asthma patients in the
ED receive an antibiotic unnecessarily [7]. In England, a
high antibiotic prescription rate (57%) was observed in
asthma patients [6]. In our previous study in China, about
70% of patients with mild to moderate acute exacerbation
of asthma received antibiotics [5].
As many as 75% of all antibiotic doses are prescribed
for RTIs, such as acute bronchitis, community-acquired
pneumonia (CAP), acute exacerbations of asthma or chronic
obstructive pulmonary disease (COPD), despite their mainly
viral cause [8]. This inappropriate use of antibiotics is
believed to be a main cause of the spread of bacterial
resistance [9]. There is a need to reduce unnecessary
antibiotic use during treatment of RTI, and much effort
has been put into the search for sensitive and specific
tools to guide antibiotic therapy in RTI patients. Clinical
trials that have used procalcitonin (PCT) to guide anti-
biotic therapy for patients with RTI have shown that a
biomarker-driven algorithm can cut antibiotic prescribing
significantly and that this can be achieved without any in-
crease in adverse events or treatment failures [5,10-17].
PCT-guided antibiotic stewardship reduced initial anti-
biotic prescription rates by 40% to 50% in patients with
LRTI (lower respiratory tract infection) presenting to
the ED [13] and by 70% to 80% in ambulatory patients
presenting to their general physicians [15] and reduced
total antibiotic exposure in CAP by 40% to 50% [10].
In our previous study, we demonstrated that PCT can
be used accurately and effectively to determine whether
acute asthma patients have bacterial infections and to
guide the use of antibiotics in the treatment of acute
exacerbation of mild to moderate asthma [5]. However,
we included few severe asthma patients in the study,
and the study had only a 6-week follow-up period. We
therefore undertook a randomized controlled study to
assess the usefulness of PCT guidance for antibiotic use
in hospitalized patients with severe acute exacerbation
of asthma, and this time included a 12-month follow-up
period.
Methods
Patients and study design
This was a randomized controlled trial. The study
was approved by the Shanghai Fifth People’s Hospital
Research Ethics Committee, and all patients or their le-
gally authorized representatives provided written informed
consent.
From January 2009 to December 2011, consecutive
patients ages 18 to 65 years who were hospitalized in the
Fifth People’s Hospital of Shanghai with severe acute
exacerbations of asthma were eligible for enrollment in
the study. Asthma was defined according to the guidelinesof the Global Initiative for Asthma [4]. A severe asthma
exacerbation was defined as at least one of the following
[18]: (1) need for systemic corticosteroids, or an increase
from a stable maintenance dose, for at least 3 days and/or
(2) hospitalization or ED visit because of asthma requiring
systemic corticosteroids. Excluded were patients with
antibiotic use within the previous 14 days, psychiatric
disorders or other inability to give written informed
consent, not being available for follow-up, severe im-
munosuppression, heart failure, cystic fibrosis, active
tuberculosis, pregnancy and chest radiography–confirmed
pneumonia.
Baseline assessment included asthma and medical his-
tory, vital signs, physical examination, routine blood tests,
chest radiography, spirometry and clinical events related
to asthma within the previous year, including asthma
exacerbations, need for systemic corticosteroids, ED visits
and hospitalizations for asthma. Spontaneously expecto-
rated sputum samples were obtained to identify potential
pathogenic microorganisms.
Serum PCT was measured using the B.R.A.H.M.S.
PCTsensitive Kryptor (B.R.A.H.M.S., Hennigsdorf, Germany),
a rapid sensitive assay with a functional sensitivity of
0.06 μg/L and a lower detection limit of 0.02 μg/L with an
assay time of less than 30 minutes.
Study intervention
Eligible patients were randomized to either PCT-guided
(PCT group) or standard antimicrobial therapy (control
group). Allocation to either intervention was conducted
according to computer-generated random numbers pro-
duced by an independent statistician. After randomization,
an opaque, sealed, sequentially numbered envelope con-
taining the PCT or control protocol was prepared for each
subject according to group assignment. The control group
received antibiotic according to the discretion of the treat-
ing physician, who was unaware of the patient’s PCT
levels. PCT levels of patients in the PCT group were
provided to their attending physicians. Patients in the
PCT group were treated with antibiotics on the basis of a
PCT algorithm validated in previous studies [5,10,12-16]:
antibiotic treatment was strongly discouraged when serum
PCT level was less than 0.1 μg/L; antibiotic treatment
was discouraged when serum PCT level was less than
0.25 μg/L; and antibiotic treatment was encouraged
when serum PCT level was higher than 0.25 μg/L. When
antibiotics were withheld from patients, a second meas-
urement of the PCT level was mandatory within 6 to
24 hours for safety reasons. The use of antibiotics was
recommended if this second measurement was higher
than 0.25 μg/L. The physicians were permitted to overrule
the algorithm, but they had to indicate the reasons for
overruling. The patients were reevaluated 12 months after
discharge.
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The primary end point was antibiotic use, expressed as
rate of antibiotic prescriptions in percentage and relative
risk of antibiotic exposure. Secondary end points inclu-
ded measures of treatment success; length of hospital
stay; clinical, laboratory and spirometry outcomes at
discharge; and results of spirometry at the 12-month
follow-up examination, as well as the results of the
Asthma Control Test (ACT) [19], the results of the Asthma
Quality of Life Questionnaire (AQLQ) [20] at the 12-
month follow-up visit and the clinical events during
the 12-month follow-up period, including numbers of
asthma exacerbations, ED visits, hospitalizations and
need for systemic corticosteroid use for treatment of
asthma.
The ACT was used to determine the level of disease
control. The overall ACT score varies from 5 (very poor
asthma control) to 25 (full asthma control), with scores
ranging from 20 to 24 defining controlled asthma, scores
ranging from 16 to 19 partly indicating controlled asthma
and scores ≤15 identifying uncontrolled asthma. The
AQLQ was used to evaluate quality of life. The AQLQ
consists of 32 items covering asthma-related symptoms
and limitations during the 2 weeks preceding adminis-
tration of the questionnaire, and responses are scored on
a scale of 1 to 7, with higher numbers indicating a better
quality of life. The validity and reliability of the ACT and
the AQLQ have been evaluated for use in Chinese patients
with asthma [21,22].
Statistical analysis
Discrete variables are expressed as percentages and
continuous variables as mean ± standard deviation (SD)
for variables normally distributed and as median with
interquartile range (IQR) for nonnormally distributed data.
Comparability of groups was analyzed by χ2 test, two-sam-
pled t-test and/or Mann-Whitney U test as appropriate.
Relative risk (RR) was calculated with 95% confidence
interval (CI). P < 0.05 was defined as statistically significant.
Assuming 90% of the patients in the control group
would use antibiotics and anticipating a 15% decrease in
antibiotic usage in the PCT group, a sample size of 158
patients (79 patients per group) was necessary to detect
a significant difference in antibiotic prescription rate
between the groups with 80% power and an α error of
0.05. To account for possible loss of patients to follow-
up, we planned to enroll 180 patients.
The time to the first occurrence of asthma-related
clinical events (exacerbation and hospitalization) was an-
alyzed using Kaplan-Meier survival curves and by the
logrank test. For outcomes during the follow-up period,
we performed per-protocol analyses. Data were analyzed
using SPSS version 16 for Windows statistical software
(SPSS, Chicago, IL, USA).Results
Study population
A total of 216 patients with severe acute exacerbations
of asthma were screened for eligibility to participate in
this study. Among this original sample, 180 were eligible
and randomized into the PCT group (n = 90) or the con-
trol group (n = 90); of these 180 patients, 169 completed
the 12-month follow-up visit, and 5 patients in the PCT
group and 6 patients in the control group were lost to
follow-up (Figure 1). The two treatment groups were
matched at baseline for demographic, clinical and labora-
tory features (Table 1).
All patients received any one or a combination of the
following medications for treatment of the exacerbation:
theophylline, corticosteroids, β2-agonists and anticholiner-
gic agents. There was a similar distribution of antibiotic
use in both groups: macrolides (56.6%; PCT group, 32
cases; control group, 49 cases; P = 0.489), fluoroquinolones
(23.1%; PCT group, 12 cases; control group, 21 cases;
P = 0.924), aminopenicillin (11.2%; PCT group, 5 cases;
control group, 11 cases; P = 0.609), cephalosporins (9.1%;
PCT group, 4 cases; control group, 9 cases; P = 0.848). A
single antibiotic was used in 108 patients (PCT group, 38
cases; control group, 70 cases; P = 0.715), and combination
therapy with two or more antibiotics was administered in
15 patients (PCT group, 6 cases; control group, 9 cases;
P = 0.715).
Sputum samples were obtained from 81 patients (PCT
group, 39 cases; control group, 42 cases), and 24 causative
microorganisms were isolated (PCT group, 11 organisms;
control group, 13 organisms). The most frequently de-
tected pathogens were Chlamydophila pneumoniae (PCT
group, 4 organisms; control group, 6 organisms), followed
by rhinovirus (PCT group, 1 organism; control group, 3
organisms) (Table 2).
The median PCT concentration was 0.113 μg/L (IQR,
0.054 to 0.270 μg/L), and 74 patients (41.1%) had PCT
levels <0.1 μg/L, 30 (16.7%) had PCT levels between 0.1
and 0.25 μg/L and 76 (42.2%) had PCT levels >0.25 μg/L.
PCT levels did not differ significantly between pa-
tients with sputum samples (0.106 μg/L; IQR, 0.050
to 0.266 μg/L) and those without (0.141 μg/L; IQR, 0.064
to 0.272 μg/L) (P = 0.145).
Primary outcome
In the PCT group, 38 patients received antibiotics ac-
cording to the PCT algorithm. Overruling was observed
in six patients with PCT <0.25 μg/L. The reasons for
overruling included receiving mechanical ventilation
(n = 3), patient’s request (n = 1) and purulent sputum
(n = 2). Four patients in the PCT group from whom
antibiotics were initially withheld (those with a PCT
level <0.25 μg/L) received an antibiotic based on a PCT
level >0.25 μg/L at the second measurement during
Figure 1 Study flow diagram displaying the number of screened, excluded, randomized and analyzed patients. PCT, Procalcitonin.
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exposure was lower in patients for whom antibiotics
were prescribed according to the algorithm based on PCT
levels compared to standard therapy (48.9% vs. 87.8%,
respectively; P < 0.001) (RR, 0.56; 95% CI, 0.44 to 0.70;
P < 0.0001). Thus, in spite of overruling, the PCT algo-
rithm permitted a 44.3% reduction in antibiotic use.
Secondary outcome
The rate of clinical success was comparable between the
two groups. Fourteen patients (15.5%) in the PCT group
and eleven (12.2%) in the control group received mech-
anical ventilation treatment (P = 0.518). The median of
antibiotic duration in the PCT group (6 days; IQR, 4 to
9 days) was similar to that in the control group (6 days;
IQR, 3 to 8 days) (P = 0.198). There were no significant
differences between groups in laboratory measures, length
of hospital stay or spirometry at discharge (Table 3).
Clinical and laboratory measures of outcome, spir-
ometry and ACT and AQLQ scores were similar at the
12-month follow-up visit in both groups (Table 4). During
the 12-month follow-up period, subsequent ED visits
occurred in 119 cases (PCT group, 61 cases; control group,
58 cases; P = 0.698), and systemic corticosteroids for ≥3 days
were needed in 89 cases (PCT group, 43 cases; control
group, 46 cases; P = 0.587). There were no significant dif-
ferences in the exacerbation rate (78.8% in PCT group vs.
82.1% in control group, respectively; P = 0.586) or in the
hospitalization rate for exacerbations of asthma (8.2%
in PCT group vs. 10.7% in control group, respectively;P = 0.582) (Table 3). The mean times to the first exacer-
bation and the first hospitalization due to exacerbation
were also similar in both groups (Figure 2).
Discussion
We observed a significant reduction in antibiotic use in
patients hospitalized with severe acute exacerbations of
asthma for whom a decision could be made on the basis
of an algorithm of PCT measurements. Importantly, with-
holding antibiotic treatment did not cause apparent harm
according to clinical and laboratory outcomes at discharge
and during the 12-month follow-up period.
Exacerbation of asthma is often precipitated by a viral
respiratory infection, and atypical bacteria such as Myco-
plasma pneumoniae and Chlamydophila pneumoniae
may play a role in its pathogenesis [23-25]. Antibiotic
use during treatment of asthma exacerbation remains
controversial, and few patients are estimated to benefit
from this type of antibiotic treatment. In the TELICAST
study [26], a total of 278 adults with acute exacerbation
of asthma were randomly assigned to receive 10 days of
treatment with oral telithromycin or placebo in addition
to usual care. Patients in the telithromycin group had a
significantly greater improvement in asthma symptoms,
but they did not show an improvement in peak expiratory
flow rates measured in the morning at home. However,
routine use of antibiotics for exacerbations of asthma is
of no benefit and may cause unwanted effects, so the
empirical use of antibiotics is not recommended. In a ran-
domized double-blind study [27], Graham and colleagues
Table 1 Characteristics of the study population at baselinea
Characteristics PCT group (n = 90) Control group (n = 90) P-value
Age in years, mean (SD) 40.4 ± 12.3 39.4 ± 11.7 0.594
Male sex, n (%) 49 (54.4) 52 (57.8) 0.652
Duration of asthma in years, mean (SD) 22.6 ± 11.7 21.8 ± 12.1 0.621
Smoking status, n (%)
Current 17 (18.9) 14 (15.6) 0.553
Former 29 (32.2) 28 (31.1) 0.872
Never 44 (48.9) 48 (53.3) 0.551
Fever, n (%) 22 (24.4) 17 (18.9) 0.365
Cough, n (%) 69 (76.7) 63 (70.0) 0.312
Sputum, n (%) 56 (62.2) 51 (56.7) 0.447
Respiratory medication, n (%)
ICS 23 (25.5) 27 (30.0) 0.505
ICS + LABA 59 (65.5) 56 (62.2) 0.641
HR, beats/min 101 ± 18 104 ± 16 0.319
RR, breaths/min 25 ± 7 24 ± 6 0.471
Systolic blood pressure, mmHg 111 ± 20 108 ± 19 0.271
pH 7.35 ± 0.08 7.36 ± 0.07 0.984
SaO2,%
b 89 ± 5 88 ± 4 0.304
PaO2, mmHg
b 61 ± 9 59 ± 8 0.178
PaCO2, mmHg
b 58 ± 16 56 ± 14 0.410
CRP, mg/L 21.1 ± 9.1 22.3 ± 9.3 0.388
WBC, ×109/L 11.8 ± 4.1 11.4 ± 3.7 0.598
PCT, μg/L 0.107 (0.052 to 0.273) 0.114 (0.055 to 0.266) 0.912
FEV1,% of predicted value 39.2 ± 9.6 39.8 ± 10.3 0.705
Clinical events related to asthma in previous year, n (%)
Asthma exacerbations 78 (86.7) 75 (83.3) 0.531
Emergency room visits 69 (76.7) 65 (72.2) 0.494
Hospitalizations 17 (18.9) 14 (15.5) 0.553
Need for systemic corticosteroids for ≥3 days 53 (58.9) 49 (54.4) 0.547
aCRP, C-reactive protein; FEV1, Forced expiratory volume in 1 second; HR, Heart rate; ICS, Inhaled corticosteroid; LABA, Long-acting β2-agonists; PaCO2, Partial
pressure of carbon dioxide; PaO2, Partial pressure of oxygen; PCT, Procalcitonin; RR, Respiratory rate; SaO2, Arterial oxygen saturation; WBC, White blood cells.
bMeasured while patient was receiving oxygen therapy. Data are presented as number (%), median (IQR) or mean ± SD.





Influenza virus, n 2 0
Rhinovirus, n 1 3
Coronavirus, n 1 1
Chlamydophila pneumoniae, n 4 6
Mycoplasma pneumoniae, n 1 0
Pseudomonas aeruginosa, n 1 0
Streptococcus pneumoniae, n 0 2
Haemophilus influenzae, n 1 1
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the hospital with acute exacerbations of asthma, with 37
exacerbations treated with amoxicillin and 34 with pla-
cebo. Response to treatment was closely monitored, but
no significant differences between groups were demon-
strated with regard to improvement measured by length
of hospital stay, time until 50% improvement in symp-
toms, patient self-assessment and respiratory function,
and symptoms and respiratory function at discharge.
More recently, in the AZISAST study [28], 55 patients
were randomly assigned to receive azithromycin and 54
were to receive placebo. Add-on treatment with azithro-
mycin did not decrease the frequency of severe exacerba-
tions of asthma and LRTI requiring antibiotics.
Table 3 Patient characteristics and outcomes at dischargea
PCT group (n = 90) Control group (n = 90) P-value
Antibiotic use, n (%) 44 (48.9) 79 (87.8) <0.001
Clinical success, n (%) 90 (100) 90 (100) 1.00
Duration of antibiotic, days 6 (4 to 9) 6 (3 to 8) 0.198
Length of hospital stay, days 9 (6 to 11) 8 (6 to 12) 0.380
Need for intubation, n (%) 14 (15.5) 11 (12.2) 0.518
FEV1,% of predicted value
Prebronchodilator 70.9 ± 12.8 72.4 ± 11.2 0.404
Postbronchodilator 75.4 ± 11.6 77.1 ± 12.5 0.345
CRP, mg/L 9.3 ± 3.4 9.7 ± 4.2 0.509
WBC, ×109/L 7.1 ± 2.1 7.4 ± 1.9 0.469
PCT, μg/L 0.041 (0.028 to 0.063) 0.046 (0.032 to 0.071) 0.723
aCRP, C-reactive protein; FEV1, Forced expiratory volume in 1 second; PCT, procalcitonin; WBC, white blood cells. Data are presented as number (%), median (IQR)
or mean ± SD.
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lenge for physicians is to identify asthma patients with
bacterial RTI for whom antimicrobial treatment is likely
to be beneficial. Patients are often prescribed antibiotics
despite clinical practice guideline recommendations
against the empiric use of antibiotics in acute exacerba-
tions of asthma [5-7]. Clinical signs and symptoms of
acute asthma and bacterial RTI overlap, as do commonly
used laboratory parameters such as C-reactive protein
(CRP) and white blood cell (WBC) count, making it
difficult for physicians to distinguish viral from bacterialTable 4 Comparison of patient characteristics and outcomes
PCT gro
Level of asthma control, n (%)
Fully controlled 13 (15.3
Controlled 48 (56.5
Partly controlled 18 (21.2
Uncontrolled 6 (7.1)
FEV1,% of predicted value
Prebronchodilator 76.7 ± 1
Postbronchodilator 83.5 ± 1
ACT score, mean (SD) 21.1 ± 3
AQLQ score, mean (SD) 5.04 ± 1
Clinical events during 12-month follow-up period
Asthma exacerbations, n (%) 67 (78.8
Per patient per year 1.54 ± 1
Emergency room visits, n (%) 61 (71.8
Per patient per year 1.01 ± 0
Hospitalizations, n (%) 7 (8.2)
Need for systemic corticosteroids for ≥3 days, n (%) 43 (50.6
aACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; FEV1, Force
number (%) or mean ± SD.infections in asthma patients [29,30]. Patients with severe
exacerbations are more often treated with antibiotics
because of high morbidity and mortality. The routine use
of standard laboratory tests such as CRP level and WBC
count seems to be motivated more by their low cost, easy
availability and historic practice rather than by their diag-
nostic accuracy. Moreover, the reliability of CRP level
and/or WBC count for guiding antimicrobial therapy is
limited by their late peak levels as well as their suboptimal
specificity, especially in patients with systemic inflamma-
tion [31,32].at the 12-month follow-up visita
up (n = 85) Control group (n = 84) P-value
) 10 (11.9) 0.520
) 51 (60.7) 0.575
) 15 (17.8) 0.586
8 (9.5) 0.561
1.8 77.9 ± 12.4 0.520
3.4 84.7 ± 12.7 0.551
.3 20.6 ± 3.5 0.324
.17 5.07 ± 1.21 0.788
) 69 (82.1) 0.586
.17 1.52 ± 1.22 0.925
) 58 (69.0) 0.698
.81 0.96 ± 0.83 0.707
9 (10.7) 0.582
) 46 (54.8) 0.587
d expiratory volume in 1 second; PCT, Procalcitonin; Data are presented as
Figure 2 Kaplan-Meier estimates of time to first asthma
exacerbation (A) and hospitalization (B) after hospital discharge.
PCT, Procalcitonin.
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systemic bacterial infections, but they remain relatively
low in patients with viral infections or inflammatory dis-
eases [33,34]. Hence, PCT levels may be used to support
clinical decision-making for the initiation and discon-
tinuation of antibiotic therapy [35]. Since the first pilot
study published in 2004 [10], PCT-guided strategies for
antibiotic treatment decision have gained much atten-
tion. Overall, it has been shown that PCT might be feas-
ible in guiding antibiotic treatment in patients with
acute exacerbations of COPD [12] as well as in limiting
treatment duration in patients with CAP [11] and severe
infectious diseases in the intensive care unit [36-39]. The
main effect has been achieved either by discouraging
antibiotic initiation or by shortening the duration of
antibiotic treatment without increased rates of adverseoutcomes [10-14,37]. The use of PCT also has prognostic
implications, as falling values correlate with good out-
comes and static or increasing values correlate with
adverse outcomes, including mortality [40,41]. More
recently, a PCT strategy was evaluated in primary
care in patients with symptoms of acute respiratory
infections, with results supporting the potential for
substantial reductions in antibiotic use in this patient
population [13,15].
Only a few asthma patients were included in two pre-
vious trials of PCT-guided therapy, [10,13]. In our own
previous study, only 34 patients with severe exacerbation
asthma were included [5]. The presently reported trial
is, to our knowledge, the first clinical study focused
on evaluation of the PCT test in its effectiveness in
guiding antibiotic treatment of severe acute exacerba-
tions of asthma.
However, some limitations of the present study should
be recognized. First, we excluded patients older than
65 years of age, which may limit the application of our
findings to older patients. Second, we did not conduct a
formal cost–benefit study. To evaluate if a PCT-based
strategy is cost-efficient under real-life conditions, cost
aspects should be carefully considered. Third, this study
was performed in a single center with a high baseline
use of antibiotics for the treatment of asthma. Reduc-
tions in antibiotic use by means of PCT therapy guid-
ance will be less in centers that already use antibiotics
for asthma less often. Fourth, because of its relatively
small sample size, our study has limited power to prove
the safety of the PCT strategy, and we cannot exclude a
potential harm of reducing antibiotic therapy on the
basis of PCT guidance. Taking into account the limited
population size in the study, a multicenter trial that
includes a large number of patients with severe exacer-
bation of asthma is desirable to validate our data. We
emphasize that any infection is too complex to be reduced
to a single cutoff of a surrogate marker, and biomarkers
should complement rather than replace good clinical prac-
tice. Certainly, results from the use of biomarkers should
be considered in light of the pretest probability of disease
presence.
Conclusions
The results of our study support the concept that PCT
guidance reduces antibiotic exposure in patients with
severe acute exacerbation of asthma without apparent
harm. Given the prevalence of asthma and the duration
of illness, a reduction in antibiotic prescriptions for the
treatment of exacerbations could result in fewer side
effects, lower costs and, in the long term, lead to dimin-
ishing drug resistance, particularly in countries such as
China, where patients are suffering from the overuse of
antibiotics [42,43].
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 Antibiotic overuse in China is normal, and patients
with severe acute exacerbations of asthma often
receive inappropriate antibiotic treatment.
 The results of this single-center study show that a
significant reduction in antibiotic use in patients
hospitalized with severe acute exacerbations of
asthma for whom a decision could be made on the
basis of an algorithm of PCT measurements.
 Withholding antibiotic treatment on the basis of
PCT guidance did not cause apparent harm for up
to 12 months.
 Additional larger multicenter studies are needed to
confirm the usefulness of PCT guidance during
treatment of severe asthma exacerbation.
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